BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Konstantinos Tziomalos. Lipid-lowering agents in the management of nonalcoholic fatty liver diseaseWorld Journal of Hepatology 2014; 6(10): 738-744 doi: 10.4254/wjh.v6.i10.738
2
Sadashiva S. Karnik, Hamiyet Unal, Jacqueline R. Kemp, Kalyan C. Tirupula, Satoru Eguchi, Patrick M. L. Vanderheyden, Walter G. Thomas, Eliot H. Ohlstein. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic StimuliPharmacological Reviews 2015; 67(4): 754 doi: 10.1124/pr.114.010454
3
Ángel Brea, Xavier Pintó, Juan F. Ascaso, Mariano Blasco, Ángel Díaz, Pedro González-Santos, Antonio Hernández-Mijares, Teresa Mantilla, Jesús Millán, Juan Pedro-Botet. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver diseaseClínica e Investigación en Arteriosclerosis (English Edition) 2017; 29(4): 185 doi: 10.1016/j.artere.2017.07.001
4
J K Dyson, Q M Anstee, S McPherson. Republished: Non-alcoholic fatty liver disease: a practical approach to treatmentPostgraduate Medical Journal 2015; 91(1072): 92 doi: 10.1136/postgradmedj-2013-100404rep
5
George B Goh, Mangesh R Pagadala, Jaividhya Dasarathy, Aynur Unalp-Arida, Ruth Sargent, Carol Hawkins, Achuthan Sourianarayanane, Amer Khiyami, Lisa Yerian, Rish Pai, Arthur J McCullough, Srinivasan Dasarathy. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver diseaseLiver International 2015; 35(3): 979 doi: 10.1111/liv.12611
6
Rosa Lombardi, Simona Onali, Douglas Thorburn, Brian R Davidson, Kurinchi Selvan Gurusamy, Emmanuel Tsochatzis. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD)Cochrane Database of Systematic Reviews 2017;  doi: 10.1002/14651858.CD011640.pub2
7
Kurinchi Selvan Gurusamy, Emmanuel Tsochatzis, Angela M Madden. Nutritional supplementation for non-alcohol-related fatty liver disease: a network meta-analysisCochrane Database of Systematic Reviews 2018;  doi: 10.1002/14651858.CD013157
8
Kurinchi Selvan Gurusamy, Douglas Thorburn, Brian R Davidson, Emmanuel Tsochatzis, Kurinchi Selvan Gurusamy. Cochrane Database of Systematic Reviews2015;  doi: 10.1002/14651858.CD011640
9
Lidija Orlic, Ivana Mikolasevic, Vesna Lukenda, Kata Anic, Ita Jelic, Sanjin Racki. Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney diseaseWiener klinische Wochenschrift 2015; 127(9-10): 355 doi: 10.1007/s00508-014-0661-y
10
Aditi Kumar, Chad Blackshear, Jose S. Subauste, Nazanene H. Esfandiari, Elif Arioglu Oral, Angela R. Subauste. Fatty Liver Disease, Women, and Aldosterone: Finding a Link in the Jackson Heart StudyJournal of the Endocrine Society 2017; 1(5): 460 doi: 10.1210/js.2017-00055
11
Diana Barb, Paola Portillo-Sanchez, Kenneth Cusi. Pharmacological management of nonalcoholic fatty liver diseaseMetabolism 2016; 65(8): 1183 doi: 10.1016/j.metabol.2016.04.004
12
Ji Hye Huh, Jang Young Kim, Eunhee Choi, Jae Seok Kim, Yoosoo Chang, Ki-Chul Sung, Tatsuo Shimosawa. The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort studyPLOS ONE 2017; 12(7): e0180951 doi: 10.1371/journal.pone.0180951
13
Kuei-Chuan Lee, Che-Chang Chan, Ying-Ying Yang, Yun-Cheng Hsieh, Yi-Hsiang Huang, Han-Chieh Lin, Rafael Aldabe. Aliskiren Attenuates Steatohepatitis and Increases Turnover of Hepatic Fat in Mice Fed with a Methionine and Choline Deficient DietPLoS ONE 2013; 8(10): e77817 doi: 10.1371/journal.pone.0077817
14
Olcay Ozveren, Cemil Izgi, Elif Eroglu, Mustafa Aytek Simsek, Ayca Turer, Zekeriya Kucukdurmaz, Veysel Cinar, Muzaffer Degertekin. Doppler Tissue Evaluation of Atrial Conduction Properties in Patients With Non-alcoholic Fatty-liver DiseaseUltrasonic Imaging 2016; 38(3): 225 doi: 10.1177/0161734615595015
15
Kurinchi Selvan Gurusamy, Emmanuel Tsochatzis, Angela M Madden. Lifestyle modifications for non-alcohol related fatty liver disease: a network meta-analysisCochrane Database of Systematic Reviews 2018;  doi: 10.1002/14651858.CD013156
16
Li-hui Yan, Biao Mu, Yue Guan, Xinyu Liu, Nan Zhao, Da Pan, Shao-zhen Wang. Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complicationsJournal of Diabetes Investigation 2016; 7(6): 889 doi: 10.1111/jdi.12518
17
Federico Carbone, Fabrizio Montecucco, François Mach, Roberto Pontremoli, Francesca Viazzi. The liver and the kidney: two critical organs influencing the atherothrombotic risk in metabolic syndromeThrombosis and Haemostasis 2013; 110(11): 940 doi: 10.1160/TH13-06-0499
18
Floriana Elvira Ionică, Simona Negreș, Ludovic Bejenaru, Cornelia Bejenaru, Cornel Chiriță. Pharmacological Approaches for Nonalcoholic Fatty Liver DiseaseRomanian Journal of Diabetes Nutrition and Metabolic Diseases 2016; 23(3) doi: 10.1515/rjdnmd-2016-0037
19
J K Dyson, Q M Anstee, S McPherson. Non-alcoholic fatty liver disease: a practical approach to treatmentFrontline Gastroenterology 2014; 5(4): 277 doi: 10.1136/flgastro-2013-100404
20
Nishika Sahini, Jürgen Borlak. Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytesProgress in Lipid Research 2014; 54: 86 doi: 10.1016/j.plipres.2014.02.002
21
Chieko Ejima, Haruna Kuroda, Sonoko Ishizaki. A novel diet-induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitisPhysiological Reports 2016; 4(21): e13016 doi: 10.14814/phy2.13016
22
Kuei-Chuan Lee, Yun-Cheng Hsieh, Ying-Ying Yang, Che-Chang Chan, Yi-Hsiang Huang, Han-Chieh Lin. Aliskiren Reduces Hepatic steatosis and Epididymal Fat Mass and Increases Skeletal Muscle Insulin Sensitivity in High-Fat Diet-Fed MiceScientific Reports 2016; 6(1) doi: 10.1038/srep18899
23
Gjin Ndrepepa, Roisin Colleran, Adnan Kastrati. Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart diseaseClinica Chimica Acta 2018; 476: 130 doi: 10.1016/j.cca.2017.11.026
24
Antonella Amato, Gaetano-Felice Caldara, Domenico Nuzzo, Sara Baldassano, Pasquale Picone, Manfredi Rizzo, Flavia Mulè, Marta Di Carlo. NAFLD and Atherosclerosis Are Prevented by a Natural Dietary Supplement Containing Curcumin, Silymarin, Guggul, Chlorogenic Acid and Inulin in Mice Fed a High-Fat DietNutrients 2017; 9(5): 492 doi: 10.3390/nu9050492
25
Seema Patel, Abdur Rauf, Haroon Khan, Tareq Abu-Izneid. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologiesBiomedicine & Pharmacotherapy 2017; 94: 317 doi: 10.1016/j.biopha.2017.07.091
26
Neel Malhotra, Melanie D Beaton. Management of non-alcoholic fatty liver disease in 2015World Journal of Hepatology 2015; 7(30): 2962-2967 doi: 10.4254/wjh.v7.i30.2962
27
Yu Wu, Kun L. Ma, Yang Zhang, Yi Wen, Gui H. Wang, Ze B. Hu, Liang Liu, Jian Lu, Pei P. Chen, Xiong Z. Ruan, Bi C. Liu. Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver diseaseLiver International 2016; 36(10): 1525 doi: 10.1111/liv.13131
28
LORENA CASTRO S., GUILLERMO SILVA P.. HÿGADO GRASO NO ALCOHÿLICORevista Médica Clínica Las Condes 2015; 26(5): 600 doi: 10.1016/j.rmclc.2015.09.006
29
Antonella Mirizzi, Isabella Franco, Carla Maria Leone, Caterina Bonfiglio, Raffaele Cozzolongo, Maria Notarnicola, Vito Giannuzzi, Valeria Tutino, Valentina De Nunzio, Irene Bruno, Claudia Buongiorno, Angelo Campanella, Valentina Deflorio, Annamaria Pascale, Filippo Procino, Paolo Sorino, Alberto Rubén Osella. Effects of Some Food Components on Non-Alcoholic Fatty Liver Disease Severity: Results from a Cross-Sectional StudyNutrients 2019; 11(11): 2744 doi: 10.3390/nu11112744
30
Meital Charni-Natan, Ronit Aloni-Grinstein, Etty Osher, Varda Rotter. Liver and Steroid Hormones—Can a Touch of p53 Make a Difference?Frontiers in Endocrinology 2019; 10 doi: 10.3389/fendo.2019.00374
31
Ángel Brea, Xavier Pintó, Juan F. Ascaso, Mariano Blasco, Ángel Díaz, Pedro González-Santos, Antonio Hernández-Mijares, Teresa Mantilla, Jesús Millán, Juan Pedro-Botet. Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hígado graso no alcohólicoClínica e Investigación en Arteriosclerosis 2017; 29(4): 185 doi: 10.1016/j.arteri.2016.06.002
32
Ji Hye Huh, Song Vogue Ahn, Sang Baek Koh, Eunhee Choi, Jang Young Kim, Ki-Chul Sung, Eung Ju Kim, Jeong Bae Park, Vincent Wong. A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG StudyPLOS ONE 2015; 10(11): e0143560 doi: 10.1371/journal.pone.0143560
33
Amedeo Lonardo, Stefano Ballestri, Giovanni Targher, Paola Loria. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver diseaseExpert Review of Gastroenterology & Hepatology 2015; 9(5): 629 doi: 10.1586/17474124.2015.965143
34
Edyta Maslak, Piotr Zabielski, Kamila Kochan, Kamil Kus, Agnieszka Jasztal, Barbara Sitek, Bartosz Proniewski, Tomasz Wojcik, Katarzyna Gula, Agnieszka Kij, Maria Walczak, Małgorzata Baranska, Adrian Chabowski, Ryan J. Holland, Joseph E. Saavedra, Larry K. Keefer, Stefan Chlopicki. The liver-selective NO donor, V-PYRRO/NO, protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat dietBiochemical Pharmacology 2015; 93(3): 389 doi: 10.1016/j.bcp.2014.12.004
35
Luciana M. A. Borém, João F. R. Neto, Igor V. Brandi, Deborah F Lelis, Sergio H. S. Santos. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief reviewHypertension Research 2018; 41(6): 394 doi: 10.1038/s41440-018-0040-6
36
Stuart McPherson, Nina Wilkinson, Dina Tiniakos, Jennifer Wilkinson, Alastair D. Burt, Elaine McColl, Deborah D. Stocken, Nick Steen, Jane Barnes, Nicola Goudie, Stephen Stewart, Yvonne Bury, Derek Mann, Quentin M. Anstee, Christopher P. Day, Vincent Wong. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitisPLOS ONE 2017; 12(4): e0175717 doi: 10.1371/journal.pone.0175717
37
Yue Li, Feng Xiong, Wen Xu, Side Liu. Increased Serum Angiotensin II Is a Risk Factor of Nonalcoholic Fatty Liver Disease: A Prospective Pilot StudyGastroenterology Research and Practice 2019; 2019: 1 doi: 10.1155/2019/5647161